A poster presented at ENDO 2021 appears to show promise for a new treatment aimed at patients with Cushing’s syndrome. The poster, presented by Strongbridge Biopharma, plc, a global commercial-stage biopharmaceutical company, announced that detailed results from the previously reported Phase 3 LOGICS study of RECORLEV® (levoketoconazole) in patients with endogenous Cushing’s syndrome were presented […]
Data Presented at ENDO 2021 Shows Promise for Treating Cushing’s Syndrome
Join the Global Movement Advancing Endocrine Science and Medicine
Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.